RPG Life Sciences Limited (RPGLIFE) AI Stock Analysis

• Market Cap: ₹31.08B
• Dividend Yield: 0.85%
• Average Volume (3M): 3.23K
• Price to Earnings (P/E): 43.4
• Beta (1Y): 0.85
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 1,270
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 13.38
• Shares Outstanding: 16,539,015
• 10 Day Avg. Volume: 8,652
• 30 Day Avg. Volume: 3,228
• PEG Ratio: 0.19
• Price to Book (P/B): 7.03
• Price to Sales (P/S): 5.71
• P/FCF Ratio: 89.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,470.00
• Price Target Upside: 7.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 76 Outperform
• Price Target: ₹2,058.00 ▼(-10.66% Downside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is driven primarily by strong financial performance—high and improving margins and a near debt-free balance sheet—tempered by weaker cash-flow conversion versus reported earnings. Technical signals are broadly neutral, and valuation looks reasonable on P/E but with a modest dividend yield.

Positive Factors

Balance-sheet conservatism

Near-zero leverage and rising equity materially reduce refinancing and interest-rate risk, giving durable financial flexibility. This conservatism supports capital allocation choices, cushions cyclical revenue swings, and underpins elevated ROE reported in FY2025, a long-term stability driver.

High and expanding margins

Consistently high gross margins and a multi-year net margin expansion reflect strong product mix and pricing power in branded formulations. Sustainable margins support reinvestment and returns, enhancing intrinsic cash generation potential if product positioning and cost structure remain stable.

Multi-year revenue expansion

Material multi-year revenue growth indicates successful market penetration of prescription-led branded products and effective distribution. A diversified therapy portfolio and field-force/channel model create recurring domestic demand, supporting durable top-line momentum over the medium term.

Negative Factors

Weak cash conversion

Earnings running ahead of cash suggest working-capital sensitivity or non-cash items inflating profits. Persistently weak conversion can constrain organic investment, dividend sustainability, and ability to fund growth without tapping reserves or external financing, a structural concern for resiliency.

Volatile free cash flow

Inconsistent free cash flow complicates forecasting and long-term capital planning. Volatility can force management to prioritize short-term liquidity over strategic investments, weaken return consistency, and increase reliance on accumulated equity buffers despite low debt.

Sustainability risk of FY2025 step-up

A pronounced single-year step-up raises the risk that FY2025 reflects cyclical, one-off, or timing effects rather than secular improvement. If underlying drivers aren't repeatable, margins and earnings could revert, undermining medium-term expectations and making future planning more uncertain.

RPG Life Sciences Limited Business Overview & Revenue Model

Company Description

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular, diabetology, orthopedics, neuropsychiatry, respiratory, nutritional, general, urology, anti-diabetic, anti-dengue, vitamins and minerals, gynecology and pediatrics, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.

How the Company Makes Money

RPGLIFE primarily makes money by selling pharmaceutical products, with revenue generated from the commercialization of its formulations portfolio. Key revenue streams typically include (1) domestic sales of branded prescription medicines to the Indian market through a field force and distribution network (sales to stockists/wholesalers and onward to pharmacies and hospitals), and (2) sales of select products through institutional or channel partners where applicable. Additional revenue may come from exports of formulations and/or out-licensing/contract manufacturing arrangements, but specific, current details on the split of domestic vs. export revenue, named partnerships, and the contribution of any contract manufacturing or licensing income are null.

RPG Life Sciences Limited Financial Statement Overview

Summary

Strong revenue growth and very high, expanding profitability alongside an exceptionally conservative (near debt-free) balance sheet. The main offsets are mixed/volatile free cash flow conversion versus elevated FY2025 earnings and a potentially unusually strong FY2025 step-up that may be hard to sustain.

Income Statement

Revenue has compounded strongly over the period (about +77% from FY2020 to FY2025), with FY2025 showing a sharp step-up versus FY2024. Profitability is a clear strength: gross margin is consistently high (~64–67%) and net margin has expanded materially (from ~10% in FY2020 to ~28% in FY2025), driving a large increase in net income. The main caution is that the FY2025 growth and profitability jump looks unusually strong versus prior years, which can raise questions on sustainability.

Balance Sheet

The balance sheet is exceptionally conservative with effectively no debt in recent years and near-zero leverage throughout, reducing refinancing and interest-rate risk. Equity has grown substantially (from ~₹1.77B in FY2020 to ~₹5.31B in FY2025), supporting a stronger capital base. Returns are also strong (return on equity rising to ~35% in FY2025). The primary limitation is that with no liquidity ratios provided, short-term balance sheet flexibility cannot be fully assessed from the available data.

Cash Flow

Cash generation is positive, but conversion is mixed. In FY2025, operating cash flow (~₹0.78B) covers only ~65% of net income, and free cash flow is ~54% of net income—suggesting earnings are running ahead of cash generation. Free cash flow has also been volatile (notably down in FY2024 versus FY2023), even though FY2025 free cash flow improved versus FY2024. Overall, cash flow quality is good but less consistent than reported profitability.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	6.66B	6.53B	5.77B	5.09B	4.37B	3.83B
Gross Profit	3.94B	4.39B	3.93B	1.70B	2.87B	2.46B
EBITDA	1.73B	1.60B	1.36B	1.08B	902.40M	718.40M
Net Income	2.15B	1.83B	876.60M	676.40M	514.80M	400.00M
Balance Sheet
Total Assets	7.06B	6.58B	5.13B	4.19B	3.45B	3.03B
Cash, Cash Equivalents and Short-Term Investments	2.24B	2.66B	1.26B	1.15B	698.00M	403.60M
Total Debt	0.00	0.00	0.00	100.00K	9.40M	20.20M
Total Liabilities	1.52B	1.27B	1.38B	1.12B	888.40M	869.40M
Stockholders Equity	5.54B	5.31B	3.75B	3.08B	2.56B	2.16B
Cash Flow
Free Cash Flow	-207.00M	418.30M	251.30M	580.90M	408.00M	497.60M
Operating Cash Flow	112.70M	778.60M	943.60M	908.20M	647.50M	582.70M
Investing Cash Flow	206.70M	-418.00M	-791.50M	-1.06B	-346.60M	-79.60M
Financing Cash Flow	-399.40M	-270.80M	-203.10M	-171.20M	-135.10M	-104.90M

RPG Life Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPGLIFE	76 Outperform	₹31.08B	43.39	―	0.85%	―	―
UNICHEMLAB	61 Neutral	₹22.04B	2.94	―	―	25.42%	―
AARTIDRUGS	57 Neutral	₹31.34B	23.17	―	0.24%	4.08%	31.52%
GUFICBIO	57 Neutral	₹29.54B	67.80	―	0.03%	7.78%	-34.68%
MOREPENLAB	57 Neutral	₹20.28B	20.54	―	0.49%	-0.29%	-29.04%
ORCHPHARMA	54 Neutral	₹27.21B	-76.20	―	―	-9.23%	-56.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

RPG Life Sciences Limited Corporate Events

RPG Life Sciences Board Clears Q3 and Nine-Month FY26 Unaudited Results

RPG Life Sciences Limited has announced that its Board of Directors, at a meeting held on 27 January 2026, approved the company’s unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025. The results, along with the statutory auditors’ limited review reports, have been submitted to the stock exchanges in compliance with SEBI’s Listing Obligations and Disclosure Requirements, underscoring the company’s ongoing financial reporting and regulatory transparency to investors and other stakeholders.

RPG Life Sciences Posts Steady Q3 FY26 Growth With Robust Margins

RPG Life Sciences reported a 4.2% year-on-year rise in revenue to Rs 180 crore for the third quarter ended 31 December 2025, with an EBITDA margin of 24%, while nine-month FY26 revenue grew 4% to Rs 530.6 crore, underscoring steady operational momentum despite a slight sequential dip in quarterly revenue. Management highlighted that the Domestic Formulations business outpaced the broader Indian Pharmaceutical Market, growing 11.8% in the first nine months of FY26 versus IPM growth of 8.2%, and reiterated the company’s strategy of disciplined execution, portfolio optimisation and building a resilient, innovation-led, people-first organisation aimed at creating sustainable value for patients, partners and stakeholders.

RPG Life Sciences Forms Wholly Owned Subsidiary RPG Active Pharma

RPG Life Sciences Limited has incorporated a wholly owned subsidiary named RPG Active Pharma Limited, which was officially registered on December 24, 2025, under a new corporate identification number issued by the Ministry of Corporate Affairs. The move, disclosed under SEBI’s Listing Regulations, signals a further structuring of the group’s pharma operations and could provide a dedicated vehicle for future growth initiatives within active pharmaceutical or related businesses, offering greater strategic and operational flexibility for the company and its stakeholders.